- This event has passed.
BE Seminar: Nanomedicine and Genome Editing Approaches for Disease Therapies
November 19 @ 11:30 am - 12:30 pm
Speaker: Dr. Gang Bao
Department of Bioengineering, Rice University
Title: Nanomedicine and Genome Editing Approaches for Disease Therapies
Abstract: The design and optimization of nanomedicine and genome editing – based tools and methods provide unprecedented opportunities for achieving better control of biological processes, and drastic improvements in disease diagnosis and treatments. Recent advances include the development of multi-functional nanoparticles and CRISPR/Cas systems for biological and medical applications.
In this talk, he will first present the recent work on magnetic nanoparticles in the lab, including the synthesis and functionalization of magnetic nanocluster for treating metastatic cancer. He will then present the design and optimization of CRISPR/Cas9-based genome editing for treating sickle cell disease. The challenges and opportunities in developing in vivo genome editing will also be discussed.
About The Speaker: Dr. Gang Bao is the Foyt Family Professor in the Department of Bioengineering at Rice University. He is also a CPRIT Senior Scholar in Cancer Research and the Director of the Cancer Bioengineering Collaborative at Rice University. Dr. Bao received his undergraduate and Master’s degrees from Shandong University in China, and his PhD degree from Lehigh University in the US. Dr. Bao is a Fellow of the American Association of Advancement in Science (AAAS), American Institute for Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), American Society of Mechanical Engineers (ASME), American Physical Society (APS), and International Academy of Medical and Biological Engineers (IAMBE).
Dr. Bao’s current research is focused on the development of genome editing and nanomedicine tools and approaches for biological and disease studies, including magnetic nanoparticle-based diagnosis and treatment of chronic diseases such as cancer, viral and non-viral based in vivo delivery methods, design and optimization of CRISPR/Cas9 for gene editing, and the application of gene editing for treating sickle cell disease and cystic fibrosis.